Finally An Attractive Entry Point Into Novo Nordisk

Core Insights - Novo Nordisk's shares have experienced a significant decline in late 2024 due to disappointing trial results for the new weight loss drug CagriSema [1] Group 1 - The trial patients of CagriSema only managed to achieve suboptimal results, leading to investor disappointment [1]